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Summary
Background In this cross-sectional study, we sought associations among severity of obstructive sleep apnea (OSA), 
renin-angiotensin-aldosterone system and blood pressure patterns in patients with resistant hypertension.
Material and methods In 65 patients with resistant hypertension we measured the apnea-hypopnea index (AHI) by 
a portable sleep recorded system and aldosterone and plasma renin activity (PRA) in response to saline infusion test. 
We also collected data on cardiovascular events, dyslipidemia, chronic kidney disease, and diabetes and performed 
24-hour blood pressure monitoring (ABPM). 
Results Baseline PRA, aldosterone and aldosterone-to-renin ratio were within normal range but aldosterone level in 
response to saline infusion was increased above normal upper limit. In ABPM, 68% of patients had an altered pattern 
of blood pressure (non-dipping or reverse dipping). AHI was inversely correlated with PRA and positively with weight, 
BMI, plasma aldosterone, aldosterone to renin ratio, and aldosterone after saline load but not with blood pressure. 
Patients with severe OSA (AHI > 30) in comparison to those with mild OSA (AHI 5–15) had significantly higher PRA 
and aldosterone (baseline and after saline load) but comparable values of blood pressure. We did not find significant 
impact of OSA severity on the frequency of abnormal blood pressure patterns. Frequencies of diabetes, abnormal lipid 
profiles, ischemic heart disease, myocardial infarction, and stroke increased with increases in severity of OSA.
Conclusions Despite of normal basal PRA and aldosterone concentration, patients with resistant hypertension and 
OSA had impaired response to saline load and a rate of this impairment depended on the severity of OSA. 
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Background
Hypertension is a key risk factor in the devel-
opment of cardiovascular diseases and one of the 
leading causes of death worldwide [1, 2]. In Poland, 
hypertension affects approximately 10.5 million of 
inhabitants. Recently, the NATPOL 2011 survey 
demonstrated the decline in number of deaths due 
to cardiovascular disease since 1990, what is un-
doubtedly associated with improvements in lifestyle 
as well as diagnosis and management of hyperten-
sion [3–5].
Obstructive sleep apnea (OSA) is a potentially se-
rious sleep disorder characterized by pauses in breath-
ing and shallow or infrequent breathing during sleep 
leading to a reduction in arterial blood oxygenation 
[6]. According to current guidelines, diagnosis of the 
condition should be confirmed by the assessment of 
indicators that are linked to the quantity of apneic 
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events per hour of sleep, such as Respiratory Dis-
turbance Index (RDI) or Apnea-Hypopnea Index 
(AHI) [7, 8]. High mortality in patients with OSA 
is associated with severity of the disease as well as co-
morbid obesity and cardiovascular events, and traffic 
accidents [8, 9].
Epidemiological association of OSA and hyper-
tension is well established. Majority of observational 
studies demonstrated robust correlations between 
AHI and blood pressure, either at baseline or over 
long-term follow-up [10, 11]. It has been demon-
strated that in patients with OSA the physiological 
nocturnal decrease of blood pressure is frequently 
altered leading to non-dipping and reverse dipping 
hypertension, which are known as independent pre-
dictors of cardiovascular risk and increased mortality 
[10, 12]. 
Pathophysiological links of OSA and hypertension 
are complex and involve at least several mechanisms. 
OSA is frequently associated with autonomic ner-
vous system derangements induced by hypercapnia 
and hypoxemia, which results in elevated catecho-
lamine levels [10, 13]. In addition, OSA correlates 
with markers of low-grade chronic inflammation, 
such as high sensitivity C-reactive protein, tumor 
necrosis factor-a, or interleukins [14]. Other stud-
ies suggested in OSA-induced hypertension a pos-
sible role of hemodynamic alternations in response 
to stress, endothelial dysfunction [10], nocturnal 
fluid redistribution [15], and up-regulation of the 
renin-angiotensin-aldosterone system [16]. How - 
e ver, the role of the latter mechanism has not yet been 
fully elucidated. Some earlier studies suggest that 
plasma aldosterone level in patients with resistant hy-
pertension is closely related to severity of OSA [16], 
especially if dietary sodium intake is increased [17]. 
In line with these findings, it was reported that pa-
tients with OSA showed elevated aldosterone excre-
tion and plasma aldosterone levels with concomitant 
suppression of plasma renin activity (PRA) [18]. On 
the other hand, some studies showed no significant 
changes in plasma aldosterone alone [19], or aldoste-
rone and PRA [20]. However, in these studies PRA 
and aldosterone were assessed only in the baseline 
conditions. To our best knowledge, there have been 
no previous reports evaluating aldosterone levels in 
the saline infusion test, which principle is that con-
trol of aldosterone is deteriorated and not suppressed 
in response to excessive salt and water load.
Therefore, in this study, we sought associations 
among severity of OSA, plasma aldosterone (both 
baseline and after saline infusion), PRA, and altered 




The study was carried out among patients with 
established diagnosis of resistant hypertension trea-
ted at university-affiliated Department of Hyperten-
sion and Internal Medicine in Szczecin. Overall, we 
included consecutive 65 hypertensive patients (19 
females, 46 males) who were referred to our unit for 
evaluation for possible OSA due to typical symp-
toms (unexplained daytime sleepiness, restless sleep, 
loud snoring, morning headaches etc.). Of them, 
18 patients (28.6%) received angiotensin converting 
enzyme inhibitors (ACEI), 37 (56.9%) angioten-
sin II receptor blockers, 39 (60%) beta blockers, 
42 (64.6%) calcium channel blockers (CCB), 49 
(75.4%) diuretics, and 21 (32.8%) other antihyper-
tensive medications. We excluded patients with prior 
diagnosis of primary hyperaldosteronism and those 
who were treated with spironolactone. Based on past 
medical history and medical records, we collected 
data on past cardiovascular events, dyslipidemia, 
chronic kidney disease, and type 2 diabetes.
Measurements
In all cases we measured height and weight and 
calculated body mass index (BMI). In 53 patients 
we performed 24-hour blood pressure monitoring 
(ABPM) (Spacelabs Healthcare) and analyzed 24-hour, 
daytime and nocturnal systolic, diastolic, and mean 
blood pressure. All patients underwent evaluation for 
OSA using a portable sleep recorder system (Embletta 
Gold 2003005; Embla Systems) which computes the 
AHI. Based on AHI, we quantified severity of OSA as 
mild (5−15 events per hour), moderate (15−30 events 
per hour) and severe (above 30 events per hour), ac-
cording to current guidelines [7, 8].
PRA (normal range: 0.51−2.64 ng/ml/h) and plasma 
aldosterone (normal range: 10−160 pg/ml) were mea-
sured using commercially available assays. From these 
measurements we calculated the aldosterone-to-renin 
ratio (ARR). Aldosterone and PRA were measured at 
the baseline and after intravenous infusion of 2,000 ml 
isotonic saline (normal range: 6−75 pg/ml). The saline 
infusion test is performed in our center as a routine 
procedure in cases with resistant hypertension.
Statistical analyses
Descriptive statistics included frequency distri-
bution for categorical variables and means, standard 
deviation, and range for continuous variables. Dif-
ferences among groups were evaluated by non-para-
metric methods (Mann-Whitney U test and Kolmo-
gorov-Smirnov test) for continuous variables and by 
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Chi square test for dichotomous variables. Logistic 
regression was used to evaluate the relationship be-
tween severity of OSA and 24-hour ABPM values 
adjusted for age and BMI. Linear Spearman’s rank 
correlation coefficients were used to determine the 
associations between AHI, blood pressure, PRA, and 
aldosterone. P values <0.05 (two-sided) were con-
sidered significant. All analyses were carried out in 
Statistica (Statsoft, Poland).
Results
As summarized in Table I, all cases were over-
weight or obese. Mean PRA, aldosterone and ARR 
were within normal range. However, mean aldoste-
rone level in response to saline infusion was increased 
above normal upper limit. Mean AHI was 31.5 ± 
± 24.9 per hour. As many as 72% of patients dis-
played abnormal lipid profiles and 19% had ischemic 
heart disease. More than 50% of patients had type 
2 diabetes. A 24-hour ABPM revealed that 68% 
of patients had an altered pattern of blood pressure 
(dipping or reverse dipping hypertension).
AHI was inversely correlated with PRA and posi-
tively with weight, BMI, plasma aldosterone, ARR, 
and aldosterone after saline load (Table II). We could 
not find significant correlations between AHI and 
blood pressure values recorded in ABPM. Similarly, 
in the regression analyses, AHI adjusted for age and 
Table I. Baseline characteristics of the study participants
Continuous variables Mean SD Range
Age (years) 54.93 11.56  27 –79
Height [m] 1.709 0.09  1.52 –1.9
Weight [kg] 100.96 21.92  58.1 –164.2
Body mass index [kg/m2] 34.45 6.63  28.0 –52.9
24-h systolic blood pressure [mmHg] 132.65 16.01  104 –197
24-h diastolic blood pressure [mmHg] 77.95 10.61  59 –117
24-h mean arterial pressure [mmHg] 96.35 12.2  78 –143
Daytime systolic blood pressure [mmHg] 134.85 15.97  109 –201
Daytime diastolic blood pressure [mmHg] 80.05 10.36  59 –119
Daytime mean arterial pressure [mmHg] 98.41 12.62  68 –145
Nocturnal systolic blood pressure [mmHg] 128.45 17.37  96 –189
Nocturnal diastolic blood pressure [mmHg] 73.61 12.0  53 –114
Nocturnal mean arterial pressure [mmHg] 91.69 14.71  54 –140
Plasma renin activity [ng/ml/h] 1.59 0.86  0.54 –5.48
Aldosterone [pg/ml] 166.07 58.02  66 –338
Aldosterone-to-renin ratio 13.06 8.21  1.1 –50.0
Aldosterone after saline infusion [pg/ml] 78.27 38.77  6.7 –154.0
Plasma renin activity after saline infusion [ng/ml/min] 2.57 4.46  0.42 –24.9
Apnoea-Hypopnoea Index 31.49 24.86  2.1 –140.2
Categorical variables Number Percent
Myocardial infarction 4 6.2
Ischaemic heart disease 12 18.5
Stroke 2 3.1
Diabetes 33 50.8
Chronic kidney disease 4 6.2
Abnormal lipid profile 47 72.3
Dippers 17 32.1
Non-dippers 27 50.9
Reverse dippers 9 17.0
24-h ABPM was measured in 53 of 65 patients
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Table II. Correlations between the Apnoea–Hypopnoea Index and 
the measured outcomes
Variable R P value
Age (years) 0.09 0.462
Height [m] 0.23 0.069
Weight [kg] 0.35 0.004
Body mass index [kg/m2] 0.27 0.024
24-hour systolic blood pressure [mmHg] –0.13 0.292
24-hour diastolic blood pressure [mmHg] –0.09 0.458
24-hour mean arterial pressure [mmHg] –0.07 0.605
Daytime systolic blood pressure [mmHg] –0.13 0.310
Daytime diastolic blood pressure [mmHg] –0.09 0.475
Daytime mean arterial pressure [mmHg] –0.09 0.477
Nocturnal systolic blood pressure [mmHg] –0.11 0.374
Nocturnal diastolic blood pressure [mmHg] –0.10 0.442
Nocturnal mean arterial pressure [mmHg] –0.09 0.484
Plasma renin activity [ng/ml/h] –0.46 0.001
Aldosterone [pg/ml] 0.57 0.001
Aldosterone-to-renin ratio 0.65 0.001
Aldosterone after saline infusion [pg/ml] 0.69 0.001
Plasma renin activity after saline infusion 
[ng/ml/h]
0.08 0.661
R refers to the Spearman rank correlation coefficient
Table III. Frequency distribution of lipid disorders, chronic kidney disease and main cardiovascular comorbidities in relation to the Apnoea– 
–Hypopnoea Index
Condition Apnoea–Hypopnoea Index
5–15/h (n = 18) 15–30/h (n = 16) > 30/h (n = 31)
Myocardial infarction 0 (0%) 2 (12.5%) 2 (6.4%)
Ischaemic heart disease 2 (11.1%) 4 (25%) 6 (19.3%)
Stroke 0 (0%) 0 (0%) 2 (6.4%)
Diabetes 2 (11.1%) 7 (43.7%) 24 (77.4%)
Chronic kidney disease 1 (5.5%) 0 (0%) 3 (9.6%)
Lipid disorders 15 (83.3%) 11 (68.7%) 21 (67.7%)
Data are presented as numbers with the condition. c2 statistics; p = 00004
BMI was not associated with systolic and diastolic 
blood pressure evaluated within the whole period of 
24 hours, daytime as well as nighttime (P > 0.05 for 
all calculations).
Along with increases in the severity of OSA, fre-
quencies of diabetes, abnormal lipid profiles and 
ischemic heart disease, and to a lesser extent, myocar-
dial infarction and stroke also increased (Table III). 
Moreover, patients with a severe type of OSA (AHI 
above 30) in comparison to those with mild OSA 
(AHI from 5 to 15) had significantly higher PRA and 
aldosterone (either at the baseline or after saline load) 
but comparable values of blood pressure in ABPM 
(Table IV). Similarly, we did not find significant 
impact of OSA severity on the frequency of normal 
and abnormal patterns of blood pressure (Table V).
Discussion
The major finding from our study is that patients 
with OSA and resistant hypertension had normal 
PRA, plasma angiotensin, and angiotensin to renin 
ratio but, as we report here for the first time, sig-
nificantly diminished aldosterone response to saline 
load. Moreover, the magnitude of this response was 
clearly associated with the severity of OSA: patients 
with AHI above 30 per hour had a 2-fold higher 
aldosterone levels than those with mild OSA. Earlier 
studies evaluating baseline activity of the renin-an-
giotensin-aldosterone system (RAAS) in OSA yielded 
inconsistent results [16, 18–20]. However, the inter-
pretation of studies, including the current study, that 
address this issue to resistant hypertension is often 
limited because treatment of this condition usually 
requires administration of medications (given in high 
doses) known to affect RAAS. ACEI and angiotensin 
receptor blockers increase PRA and lower aldoste-
rone levels. Beta blockers can reduce PRA, leading to 
a falsely elevated angiotensin to renin ratio, whereas 
dihydropyridine CCB can reduce aldosterone levels, 
potentially leading to a falsely normal angiotensin to 
renin ratio in primary hyperaldosteronism. Majority 
of diuretics tend to induce secondary hyperaldoste-
ronism and spironolactone, an aldosterone recep-
tor antagonist, can raise plasma renin levels. In this 
study, to minimize the drug class effect on RAAS, we 
excluded cases treated with spironolactone.
Aside from these methodological challenges, our 
results suggest that RAAS in OSA may be up-reg-
ulated regardless of baseline PRA and aldosterone 
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Table IV. Differences in studied parameters between patients with low and high the Apnoea–Hypopnoea Index
Variable Apnoea–Hypopnoea Index
5–15 (n=15) > 30 (n = 26) P value
Age (years)  53.27 ± 12.18  57.32 ± 10.72 0.352
Height [m]  1.67 ± 0.08  1.72 ± 0.09 0.057
Weight [kg]  93.12 ± 16.31  106.2 ± 26.7 0.093
Body mass index [kg/m2]  33.25 ± 4.62  35.62 ± 8.26 0.431
24-hour systolic blood pressure [mmHg]  134.4 ± 14.3  131.2 ± 17.0 0.231
24-hour diastolic blood pressure [mmHg]  78.47 ± 9.13  77.43 ± 11.49 0.390
24-hour mean arterial pressure [mmHg]  96.20 ± 9.65  93.50 ± 22.21 0.361
Daytime systolic blood pressure [mmHg]  137.05 ± 14.0  133.6 ± 17.26 0.122
Daytime diastolic blood pressure [mmHg]  80.76 ± 8.78  79.50 ± 11.59 0.393
Daytime mean arterial pressure [mmHg]  98.80 ± 9.39  97.96 ± 15.12 0.784
Nocturnal systolic blood pressure [mmHg]  129.8 ± 15.54  126.4 ± 18.35 0.290
Nocturnal diastolic blood pressure [mmHg]  74.29 ± 10.12  72.80 ± 12.78 0.388
Nocturnal mean arterial pressure [mmHg]  91.80 ± 10.23  90.15 ± 17.02 0.359
Plasma renin activity [ng/ml/h]  2.11 ± 1.15  1.25 ± 0.59 0.0001
Aldosterone [pg/ml]  139.3 ± 46.5  188.83 ± 44.77 0.0001
Aldosterone-to-renin ratio  8.01 ± 6.17  17.57 ± 8.33 0.0001
Aldosterone after saline infusion [pg/ml]  47.67 ± 21.93  104.48 ± 31.35 0.0001
Plasma renin activity after saline infusion [ng/ml/h]  3.54 ± 6.59  2.62 ± 1.81 0.590
Apnoea–Hypopnoea Index  7.53 ± 8.55  51.30 ± 21.06 0.0001
Table V. Blood pressure patterns in relation to the severity of obstructive sleep apnoea
Blood pressure pattern Apnoea–Hypopnoea Index
5–15 (n = 18) 15–30 (n = 16) > 30 (n = 30)
Dipping 6 (33%) 7 (44%) 16 (53%)
Non-dipping 11 (61%) 6 (38%) 10 (33%)
Reverse dipping 1 (6%) 3 (18%) 5 (16%)
c2 statistics; p = 0.24
levels, the more that we found moderate to strong 
correlations between AHI and aldosterone (baseline 
and after suppression with saline), and ARR. These 
findings may be clinically relevant because aldoste-
rone seems to play pathophysiological role in the re-
lation between hypertension and OSA [16, 21–23].
It was demonstrated that aldosterone excess con-
tributed to greater severity of OSA [21, 24]. In fact, 
the association between OSA and RAAS is even 
more complex because it may be influenced by other 
factors, such as coexisting obesity, excessive fat ac-
cumulation in depots outside of the subcutaneous 
tissue, or insulin resistance. Early studies showed 
higher aldosterone concentration in obese subjects 
than in their normal weight counterparts what might 
predispose them to the development of resistant hy-
pertension [25]. Recently, Buglioni et al. found that 
aldosterone analyzed as a continuous variable was 
associated with hypertension, obesity, metabolic syn-
drome, high triglycerides, and chronic kidney diseas-
es [26]. They suggested that aldosterone, even within 
the normal range, may be a biomarker of cardiorenal 
and metabolic disease. Accordingly, higher levels of 
aldosterone are present in obese and insulin-resistant 
patients as well as rodent models, leading to inflam-
mation and oxidative stress and contributing to im-
paired insulin signaling, decreasing glucose transport 
and vascular dysfunction, and as a consequence − to 
the development of cardiovascular disease [27–30].
Reinforcing this suggestion, aldosterone has been 
shown to inhibit insulin effects in the vasculature in-
ducing vascular insulin resistance [31]. On the other 
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hand, the positive associations between aldosterone 
concentrations with plasma glucose, insulin, C-pep-
tides, and indices of insulin resistance and beta cell 
destruction has also been reported in a population of 
patients with essential hypertension [32], whereas sur-
gical treatment or treatment with aldosterone antago-
nists in subjects with hyperaldosteronism rapidly and 
persistently restored sensitivity to insulin [33]. How-
ever, causal relationships between RAAS, obesity and 
glucose tolerance have not been yet elucidated [34]. 
In our study we found high rates of obesity and type 2 
diabetes. Therefore, we cannot exclude that at the time 
of evaluation the associations between severity of OSA 
and RAAS components measured in this study were 
not triggered or magnified by coexisting excess body 
weight, insulin resistance, or resistant hypertension.
In our sample we also found high rates of cardio-
vascular events. This finding confirms a widely ac-
cepted view that a cluster of metabolic abnormalities, 
including obesity, hypertension, diabetes, abnormal 
lipid profiles, and OSA is a key risk factor for cardio-
vascular disease.
In conclusion, despite of normal basal PRA and 
aldosterone concentration, patients with resistant hy-
pertension and OSA had impaired response to saline 
load and a rate of this impairment depended on the 
severity of OSA.
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